Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Binghe Xu

Showing results (11-20 of 406) with videos related to

Pageof 41
Sort By:
Cancer Innovation|June 8, 2026
Expert Consensus on the Clinical Application of Poly ADP Ribose Polymerase Inhibitors in Breast Cancer (2025 Edition)Fei Ma, Binghe Xu,
Signal Transduction and Targeted Therapy|October 23, 2019
Targeted therapeutic options and future perspectives for HER2-positive breast cancerJiani Wang, Binghe Xu
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|January 12, 2026
Epidemiology, early detection, and management of breast cancer in China: A comprehensive reviewHangcheng Xu, Binghe Xu
The Lancet. Oncology|January 18, 2021
CDK4/6 inhibition in early-stage breast cancer: how far is it from becoming standard of care?Binghe Xu, Ying Fan
Breast Cancer (Dove Medical Press)|March 4, 2021
Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese PerspectivePeng Yuan, Binghe Xu
Frontiers of Medicine|August 14, 2020
Progress in systemic therapy for triple-negative breast cancerHongnan Mo, Binghe Xu
Clinical Breast Cancer|September 12, 2018
Distinct Characteristics and Metastatic Behaviors of Late Recurrence in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Breast Cancer: A Single Institute Experience of More Than 10 YearsXuelian Chen, Ying Fan, Binghe Xu
Journal of Cancer|January 6, 2021
Novel biomarkers and prediction model for the pathological complete response to neoadjuvant treatment of triple-negative breast cancerYiqun Han, Jiayu Wang, Binghe Xu
Breast (Edinburgh, Scotland)|September 26, 2020
Clinicopathological characteristics and prognosis of breast cancer with special histological types: A surveillance, epidemiology, and end results database analysisYiqun Han, Jiayu Wang, Binghe Xu
The Oncologist|January 16, 2015
In replyBinghe Xu, Andrew Seidman, Stephen Chan
Pageof 41

Showing results (11-20 of 406) with videos related to

Sort By:
Pageof 41
Cancer Innovation|June 8, 2026
Expert Consensus on the Clinical Application of Poly ADP Ribose Polymerase Inhibitors in Breast Cancer (2025 Edition)Fei Ma, Binghe Xu,
Signal Transduction and Targeted Therapy|October 23, 2019
Targeted therapeutic options and future perspectives for HER2-positive breast cancerJiani Wang, Binghe Xu
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|January 12, 2026
Epidemiology, early detection, and management of breast cancer in China: A comprehensive reviewHangcheng Xu, Binghe Xu
The Lancet. Oncology|January 18, 2021
CDK4/6 inhibition in early-stage breast cancer: how far is it from becoming standard of care?Binghe Xu, Ying Fan
Breast Cancer (Dove Medical Press)|March 4, 2021
Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese PerspectivePeng Yuan, Binghe Xu
Frontiers of Medicine|August 14, 2020
Progress in systemic therapy for triple-negative breast cancerHongnan Mo, Binghe Xu
Clinical Breast Cancer|September 12, 2018
Distinct Characteristics and Metastatic Behaviors of Late Recurrence in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Breast Cancer: A Single Institute Experience of More Than 10 YearsXuelian Chen, Ying Fan, Binghe Xu
Journal of Cancer|January 6, 2021
Novel biomarkers and prediction model for the pathological complete response to neoadjuvant treatment of triple-negative breast cancerYiqun Han, Jiayu Wang, Binghe Xu
Breast (Edinburgh, Scotland)|September 26, 2020
Clinicopathological characteristics and prognosis of breast cancer with special histological types: A surveillance, epidemiology, and end results database analysisYiqun Han, Jiayu Wang, Binghe Xu
The Oncologist|January 16, 2015
In replyBinghe Xu, Andrew Seidman, Stephen Chan
Pageof 41